MDL | MFCD00003660 |
---|---|
Molecular Weight | 372.50 |
Molecular Formula | C23H32O4 |
SMILES | C[C@@]12[C@@H](C(COC(C)=O)=O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC2)=O |
Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria [1] [2] .
Human Endogenous Metabolite |
Deoxycorticosterone acetate (2.5 mg/d; s.c. implantation; 42 d; 2 mg/d
Tamoxifen
(HY-13757A) pre-treatment) induces hypertension by increasing blood pressure and cardiac hypertrophy in mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | MR (mineralocorticoid receptor) mutant mice (MR Cdh5Cre ) and MR wild-type mice (MR wild-type ) treated with unilateral nephrectomy (12-week-old) [1] |
Dosage: | 2.5 mg/d |
Administration: | Subcutaneous implantation; 42 days; treated with 2 mg Tamoxifen (HY-13757A) (20 mg/mL in sunflower oil and 10% ethanol; i.p.; once daily on 5 consecutive days) at least 4 weeks before nephrectomy |
Result: |
Increased the blood pressure without differences between both genotypes (MR
Cdh5Cre
and MR
wild-type
).
Resulted glomerular injury and proteinuria, renal inflammation and fibrosis. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 41.67 mg/mL ( 111.87 mM ; ultrasonic and warming and heat to 80°C)
H 2 O : 1 mg/mL ( 2.68 mM ; ultrasonic and warming and heat to 80°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.6846 mL | 13.4228 mL | 26.8456 mL |
5 mM | 0.5369 mL | 2.6846 mL | 5.3691 mL |
10 mM | 0.2685 mL | 1.3423 mL | 2.6846 mL |